Suppr超能文献

一项建立链激酶第二个国际标准的合作研究。

A collaborative study to establish the second international standard for streptokinase.

作者信息

Heath A B, Gaffney P J

机构信息

National Institute for Biological Standards and Control, South Mimms, Herts, UK.

出版信息

Thromb Haemost. 1990 Oct 22;64(2):267-9.

PMID:2270534
Abstract

An International Standard for Streptokinase--Streptodornase (62/7) has been used to calibrate high purity clinical batches of SK since 1965. An international collaborative study, involving six laboratories, was undertaken to replace this standard with a high purity standard for SK. Two candidate preparations (88/826 and 88/824) were compared by a clot lysis assay with the current standard (62/7). Potencies of 671 i.u. and 461 i.u. were established for preparations A (88/826) and B (88/824), respectively. Either preparation appeared suitable to serve as a standard for SK. However, each ampoule of preparation A (88/826) contains a more appropriate amount of SK activity for potency testing, and is therefore preferred. Accelerated degradation tests indicate that preparation A (88/826) is very stable. The high purity streptokinase preparation, coded 88/826, has been established by the World Health Organisation as the 2nd International Standard for Streptokinase, with an assigned potency of 700 i.u. per ampoule.

摘要

自1965年以来,链激酶-链道酶国际标准品(62/7)一直用于校准高纯度临床批次的链激酶。开展了一项由六个实验室参与的国际协作研究,以用链激酶的高纯度标准品取代该标准品。通过凝块溶解试验,将两种候选制剂(88/826和88/824)与现行标准品(62/7)进行比较。制剂A(88/826)和制剂B(88/824)的效价分别确定为671国际单位和461国际单位。两种制剂似乎都适合用作链激酶的标准品。然而,制剂A(88/826)的每个安瓿含有更适合效价测试的链激酶活性量,因此更受青睐。加速降解试验表明制剂A(88/826)非常稳定。编码为88/826的高纯度链激酶制剂已被世界卫生组织确立为链激酶的第2个国际标准品,每安瓿指定效价为700国际单位。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验